Recent Updates — SNOA

On October 6, 2026, Sonoma Pharmaceuticals adopted a new Section 382 rights agreement with Computershare Inc. to replace an expiring predecessor agreement. The plan issues one preferred stock purchase right for each outstanding share of common stock as of the October 13, 2026 record date. Each right entitles holders to purchase one-thousandth of a Series B Preferred Share at $10.00 per unit. The rights are designed to prevent ownership changes that would limit the company's ability to utilize net operating loss carryforwards and other tax benefits under Internal Revenue Code Section 382. Rights become exercisable if any person or group acquires 4.99% or more of the common stock, subject to specific grandfathering provisions for existing large shareholders. The agreement expires on October 6, 2036, or when the tax benefits are exhausted. Sonoma Pharmaceuticals operates in the pharmaceutical industry, developing and commercializing medical devices and drug delivery systems.

Sonoma Pharmaceuticals, Inc. filed a supplement to its Prospectus Supplement to increase the aggregate offering price of common stock under its At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. from the previous amount to $3,641,703. Since September 26, 2025, the company has sold 173,073 shares for a total of $574,633. Sonoma Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes commercial products for the treatment of pain and pain-related disorders.